healthcare stocks posts
FeedPosted Mar 23rd 2011 3:30PM by Steven Halpern (RSS feed)
Filed under: Apple Inc (AAPL), Newsletters, Bristol-Myers Squibb (BMY), Stocks to Buy
"According to the Spectrem Group, which recently polled the country's wealthiest people, they're the most optimistic they've been in months," says Marc Lichtenfeld.
The contributing editor to Investment U explains, "Let's take a look at 3 stocks that millionaires (and aspiring ones) should pay attention to: Apple (AAPL), Bristol-Myers Squibb (BMY) and Varian Medical Systems (VAR).
"And according to Fidelity, 83% of millionaires surveyed said the financial crisis did not shake their confidence in investing. And of those who said they'll invest more money in the stock market, nearly 60% of them plan to buy technology stocks. And just under half expect to acquire pharmaceutical and healthcare stocks.
Continue reading Three Favorite Stocks of Wealthy Investors
Posted Feb 17th 2011 1:00PM by Steven Halpern (RSS feed)
Filed under: Newsletters, Mutual Funds
"We own a healthy dose of Fidelity Select Healthcare (FSPHX) in each of our model portfolios," says fund expert Jim Lowell.
The editor of Fidelity Investor explains, "Manager Eddie Yoon and I caught up this month. His command of the sector and his growth-oriented discipline continue to serve us well on both our risk-adjusted and real return fronts/
"Of course, healthcare (representing nearly 16% of our total GDP) is unlike any other sector in the S&P. It is so diversified and global, so interrelated to technology, manufacturing, and R&D, so dependent upon delivering real goods and services for consumer consumption, that it is almost an economy unto itself.
Continue reading Fidelity Select Healthcare (FSPHX): The Right Prescription
Posted Feb 8th 2011 11:00AM by Steven Halpern (RSS feed)
Filed under: Newsletters, Stocks to Buy
"The visible growth story at Jazz Pharmaceuticals (JAZZ) is the narcolepsy treatment Xyrem, which accounts for 85% of revenues," says growth stock specialist Mike Cintolo.
The editor of Cabot Top Ten Weekly Report explains, "But Jazz has great potential to make big money with other drugs too-all of which focus on the chemistry of the brain.
"Thanks to patents, Jazz has a decade to run with Xyrem before generic competitors can enter the market. Meanwhile, its drugs have potential to treat and/or cure obsessive-compulsive disorders, anxiety disorders, fibromyalgia, epilepsy and restless leg syndrome.
Continue reading All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety
Posted Dec 7th 2010 10:50AM by Steven Halpern (RSS feed)
Filed under: Newsletters, Stocks to Buy, Obama Picks

"One thing that will continue to play out -- regardless of the direction of health care policy and law -- consumers and spenders of health care dollars need to spend less," notes
Neil George.
The editor of
The Pay Me Strategy explains, "One solution for more efficient spending comes from Express Scripts (
ESRX), which is right in the thick of the issue of prescription drugs and drug costs. The Saint Louis-based company is one of the leaders in pharmaceutical benefit management.
"To get lower drug prices -- you need to not only advance the efficiency of drug processing and distribution -- but also the advancement of cheaper generic drugs.
Continue reading Express Scripts (ESRX): The Right Prescription?
Posted Nov 17th 2010 5:30PM by Joseph Lazzaro (RSS feed)
Filed under: Stocks to Buy
Cardinal Health's shares (CAH), first discussed here on April 27, 2009, at a pre-spin-off price of $34.22, continued to meander over the past four months, but I still like the business model at this juncture. Here's why.
Cardinal probably will post a 3% to 5% 2010 revenue rise, followed by a 2% to 4% increase in 2011.
Key operation factors working in CAH's favor include increased prescription sales, modest pricing power, better performance of wider-margin generic drugs, lower customer attrition, and more-effective cost controls. Cardinal's medical unit, however, will lag other divisions, due to soft hospital markets.
Continue reading Cardinal Health Is Trying Investors' Patience
Posted Oct 25th 2010 11:00AM by Steven Halpern (RSS feed)
"Our model portfolios are based on selecting stocks that meet the investing criteria of "legendary" investors," explains John Reese.
The editor of Validea continues, "Sanofi-Aventis (SNY), which is involved in pharmaceuticals and human vaccines, earns a Guru Score of 100% based on the value investing strategy of Benjamin Graham.
"In its pharmaceutical activity, the company specializes in six therapeutic areas: diabetes, oncology, thrombosis and cardiovascular, central nervous system (CNS), and internal medicine.
Continue reading Sanofi-Aventis (SNY): A Ben Graham Value Buy
Next Page >